168 related articles for article (PubMed ID: 8807146)
1. Clinical pharmacologists and drug regulation--future perspective in Japan.
Hirokawa K
Br J Clin Pharmacol; 1996 Jul; 42(1):63-71. PubMed ID: 8807146
[TBL] [Abstract][Full Text] [Related]
2. [Development of an anticancer drug in Japan based on a new clinical trial system].
Nakashima H; Nakano S
Gan To Kagaku Ryoho; 1998 Feb; 25(3):287-94. PubMed ID: 9492818
[TBL] [Abstract][Full Text] [Related]
3. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
Pflieger M; Bertram D
Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
[TBL] [Abstract][Full Text] [Related]
4. [Implementation of new Japanese GCP and the quality of clinical trials--from the standpoint of the pharmaceutical industry].
Ebi O
Gan To Kagaku Ryoho; 1997 Oct; 24(13):1883-91. PubMed ID: 9350232
[TBL] [Abstract][Full Text] [Related]
5. Clinical trials and the new good clinical practice guideline in Japan. An economic perspective.
Ono S; Kodama Y
Pharmacoeconomics; 2000 Aug; 18(2):125-41. PubMed ID: 11067647
[TBL] [Abstract][Full Text] [Related]
6. [Development of anti-cancer drugs under new renewed GCP--from the viewpoint of drug development company developer].
Ueno T; Kobayashi T; Inoue K; Yanagi Y; Yamada Y
Gan To Kagaku Ryoho; 1998 Apr; 25(5):663-70. PubMed ID: 9571963
[TBL] [Abstract][Full Text] [Related]
7. [Chapter 3. Transitions in clinical trials and appropriate use of drugs in Japan (1980-2010)].
Koshimizu T
Yakushigaku Zasshi; 2014; 49(1):50-63. PubMed ID: 25272637
[TBL] [Abstract][Full Text] [Related]
8. [Our policy and future tasks related to ICH in anti-cancer drug development--a discussion from the viewpoint of an enterprise].
Ekimoto H
Gan To Kagaku Ryoho; 1997 Jan; 24(2):229-37. PubMed ID: 9030236
[TBL] [Abstract][Full Text] [Related]
9. Japanese regulatory system for approval of off-label drug use: evaluation of safety and effectiveness in literature-based applications.
Shimazawa R; Ikeda M
Clin Ther; 2012 Oct; 34(10):2104-16. PubMed ID: 23036337
[TBL] [Abstract][Full Text] [Related]
10. [Impact of the last 15 years: from PMDEC to PMDA --looking back at the first stage of the PMDEC].
Morimoto K; Fujiwara Y; Kawahara A
Yakushigaku Zasshi; 2011; 46(1):38-50. PubMed ID: 22164689
[TBL] [Abstract][Full Text] [Related]
11. [Review process of new oncology drug application in Japan--role of MD reviewer].
Fujiwara Y
Gan To Kagaku Ryoho; 1999 Jan; 26(2 Suppl):196-203. PubMed ID: 9987519
[TBL] [Abstract][Full Text] [Related]
12. Identification of Drug Characteristics for Implementing Multiregional Clinical Trials Including Japan.
Rokuda M; Matsumaru N; Tsukamoto K
Clin Ther; 2018 Feb; 40(2):284-295. PubMed ID: 29361305
[TBL] [Abstract][Full Text] [Related]
13. [ICH-GCP Guideline: quality assurance of clinical trials. Status and perspectives].
Englev E; Petersen KP
Ugeskr Laeger; 2003 Apr; 165(16):1659-62. PubMed ID: 12756823
[TBL] [Abstract][Full Text] [Related]
14. [Experience as a model hospital for new good clinical practice (GCP) regulations].
Tanaka S
Gan To Kagaku Ryoho; 1998 Aug; 25(10):1467-73. PubMed ID: 9725036
[TBL] [Abstract][Full Text] [Related]
15. [In order to perform clinical trials efficiently in Japan--important issues in medical institutions raised by the GCP on-site review].
Akiyama T; Furuta M; Yamada H
Nihon Kokyuki Gakkai Zasshi; 2006 Aug; 44(8):541-9. PubMed ID: 16972610
[TBL] [Abstract][Full Text] [Related]
16. Industry perspectives on ICH guidelines.
Rockhold FW
Stat Med; 2002 Oct; 21(19):2949-57. PubMed ID: 12325111
[TBL] [Abstract][Full Text] [Related]
17. [Introduction of new GCP (good clinical practice)].
Miyake S
Gan To Kagaku Ryoho; 1998 Apr; 25(5):645-9. PubMed ID: 9571961
[TBL] [Abstract][Full Text] [Related]
18. [Historical sketch of modern pharmaceutical science and technology (Part 4). Post World War II 50 years].
Yamakawa K
Yakushigaku Zasshi; 1995; 30(2):75-90. PubMed ID: 11613536
[TBL] [Abstract][Full Text] [Related]
19. Future European health care: cost containment, health care reform and scientific progress in drug research.
Emilien G
Int J Health Plann Manage; 1997; 12(2):81-101. PubMed ID: 10173136
[TBL] [Abstract][Full Text] [Related]
20. Integration of pediatric aspects into the general drug development process.
Rose K
Ernst Schering Res Found Workshop; 2007; (59):123-34. PubMed ID: 17117719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
